This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PAN90806 Ophthalmic Solution
Description: PAN-90806 is an inhibitor of VEGF, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased blood vessel permeability (leakage from blood vessels).
OSI (Astellas) and PanOptica
In January 2010, PanOptica announced that it had licensed exclusive worldwide ophthalmic rights to PAN-90806 from OSI Pharmaceuticals, a wholly owned subsidiary of Astellas in exchange for up-front cash, equity interest in PanOptica, and potential future milestones and royalties. Financial terms of the agreement have not been disclosed.
Partners: Astellas Pharma, Inc.
Additional information available to subscribers only: